Emerging pathways can help cell and gene therapies become commercially viable for intractable diseases, even with uneven scalability and consistency.

NorthStrive Biosciences Inc. (“NorthStrive Biosciences”), a wholly owned subsidiary of PMGC Holdings Inc. (“PMGC” or the “Company”) (NASDAQ: ELAB), today announced a key development milestone for its ...

Next-generation engineered probiotic targeting myostatin and Activin-A pathways advances toward clinical readiness across ...

Cells can be thought of as cities, with factories, a transport system, and lots of building activity. An international team ...

Iovance chose Philadelphia for its manufacturing operations because of the region's proximity to airports and history of ...

As cell and gene therapy developers face rising pressure to produce therapies faster and at lower cost, the industry is ...

Rapid solar manufacturing expansion masks structural gaps, as heavy reliance on imported cells highlights imbalance in ...

Principal Scientist Anders Cai Holm Hansen explains how CDMO AGC Biologics uses its global, single-use network and a strategy ...

Collaboration builds on CAR-T commercialization in New Zealand and supports expansion across Australia, North America and other international marketsWELLINGTON, New Zealand and KINGSTON, Ontario, ...

Officials at Caring Cross emphasize that the organization is dedicated to ensuring the global affordability of advanced therapies.

The regenerative medicine market is projected to reach $578 billion by 2033. Cell therapy alone surpassed $8.2 billion this year. And yet the central challenge of the entire sector remains unresolved: ...